Aktienanalyse zu Arrowhead Pharmaceuticals, Inc. (ARWR)ARWRArrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Arrowhead Pharmaceuticals Inc is a good buy right now due to its current price of $62.75 being significantly lower than the analyst price targets of $108 and $120. Additionally, the company has shown a strong revenue increase, reporting $75.3 million for Q3 2026, up from $27.8 million year-over-year, indicating a positive trend in financial performance. However, the main risk is the widening net loss of $194.3 million in Q3 2026, which could impact investor confidence.